Clinical Trial Update: TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease

View source ↗

Summary

Clinical trial update on TRx0237 (LMTX) for Alzheimer's disease, indicating the study is currently available for enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• LMTX (TRx0237) (tau aggregation inhibitor; methylthionininium derivative)

Snippet

Sponsor: TauRx Therapeutics Ltd | Conditions: Alzheimer Disease | Status: AVAILABLE